As stated in the report of Credit Suisse, the third quarterly revenue of SH PHARMA (02607.HK) +0.080 (+0.414%) Short selling $643.69K; Ratio 4.148%
shot up 27.7% to RMB 24.703 billion. Excluding special items, the
increasing rate of earnings recorded a year-on-year increase of 13.9%,
an acceleration from 5.8% in the first half of the year. It is believed
that the annual core earnings will record a double-digit growth. The
target price of Shanghai Pharmaceuticals was lifted from $15.04 to $19,
which represents 15x of P/E. The rating was maintained at Neutral.
BASETROPHY GP (08460.HK) Expects Jan-Aug Results to Swing to Loss BASETROPHY GP (08460.HK) -0.013 (-8.280%) issued a profit warning. The group is expected to record a loss for the eight months ended 31 August 2017 as compared with a net profit for the same period of 2016, mainly due to the decrease in revenue recognised by the group and increase of listing expense
Comments
Post a Comment